{"companyId":272661,"requestedLanguage":"en","resolvedLanguage":"en","availableLanguages":["en","ja"],"companyName":"Sagimet Biosciences Inc.","headOfficeLocation":"155 Bovet Road, Suite 303, San Mateo, CA 94402, United States","presidentName":"David Happel","companySummary":null,"stockCode":"SGMT","currency":"USD","capital":null,"sales":null,"employees":null,"employeesConsolidated":null,"humanCheck":false,"domains":["sagimet.com"],"businessContents":["Develops therapeutics for metabolic diseases, including liver diseases.","Develops fatty acid synthase inhibitors for nonalcoholic steatohepatitis treatment."],"relations":[],"dataSources":[{"detailNumber":1,"url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465926026140/sgmt-20251231x10k.htm","scoreAbout":500,"scoreBusiness":0,"scoreGroup":0,"scoreCustomer":0}]}